Trump Administration Announces Pharmaceutical Pricing Agreements Under MFN Framework

The Trump administration has announced most favored nation (MFN) pricing agreements with pharmaceutical manufacturers, though significant details remain unclear. These agreements aim to tie U.S. drug prices to lower international reference prices. The scope, enforcement mechanisms, and participating manufacturers have not been fully disclosed. For Medicaid managed care organizations, any changes to federal drug pricing benchmarks could affect supplemental rebate negotiations, pharmacy benefit management contracts, and budget projections.

Pharmacy · Managed Care